Profile data is unavailable for this security.
About the company
Ascentage Pharma Group International is an investment holding company principally engaged in developing novel small therapies for cancers, hepatitis B virus (HBV) and certain age-related diseases. The Company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The Company conducts businesses within the domestic market and to overseas markets, including the United States.
- Revenue in HKD (TTM)240.02m
- Net income in HKD-1.00bn
- Incorporated2017
- Employees583.00
- LocationAscentage Pharma Group International218 Xinghu StreetBuilding B7, 7th FloorSuzhou ChinaCHN
- Websitehttps://www.ascentage.cn/
More ▼